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Summary 
Natural killer cell stimulatory factor (NKSF), or interleukin 12 (ID12), is a heterodimeric lymphokine 
produced by B cells that has multiple effects on T and NK cell functions. NKSF at concentrations 
as low as 0.4 pM enhances the spontaneous cytotoxic activity of peripheral blood lymphocytes 
(PBL) against a variety of tumor-derived target cell lines and virus-infected target cells. The combined 
treatment of PBL with NKSF and ID2 results in a less than additive enhancement of cytotoxicity. 
NKSF enhances the cytotoxic activity of spontaneously cytotoxic CD16+CD5 -  NK cells and 
does not confer cytotoxic activity to CD16-CD5 + T  cells.  PBL from patients infected with 
human immunodeficiency virus (HIV) have significantly lower cytotoxic activity against tumor- 
derived target cells and virus-infected target cells than PBL from control healthy donors. Treatment 
of PBL from HIV-infected patients with NKSF and/or Ib2 results in an increase of NK cell 
cytotoxicity against both types of target cells to levels similar to or higher than those of untreated 
PBL from healthy donors.  PBL from HIV-infected patients produce interferon 3' in response 
to NKSF and/or II.-2, although at levels 5- or 10-fold lower than those produced by PBL from 
healthy donors. The multiple biological effects of NKSF, its activity at very low molar concentrations, 
and its ability to synergize with other physiological stimuli suggest that NKSF/ID12 is a lymphokine 
likely to have physiological importance and considerable therapeutic potential. 
N 
'atural killer cell stimulatory factor (NKSF) 1 is a het- 
erodimeric lymphokine composed of a heavy (p40) and 
a light chain (p35) covalently linked (1, 2). The NKSF p40 
chain belongs to the recently defined cytokine receptor family 
of proteins and has structural homology with the cellular 
receptor for II.-6 (3). NKSF has also recently been described 
as cytotoxic lymphocyte maturation factor (CLMF); the name 
I1.-12 has been proposed for this lymphokine (4,  5). 
NKSF was originally purified from the cell-free superna- 
rant fluid of phorbol diester-activated human B lymphoblastoid 
cell lines. The two genes coding for the p40 and p35 chains 
1 Abbreviations  used  in  this paper:  n,  natural;  NKSE  natural  killer  cell 
stimulatory factor. 
of NKSF have been molecularly cloned; simultaneous trans- 
fection of mammalian cells with the two genes is necessary 
for the production of biologically active NKSF (2, 5). How- 
ever,  B lymphoblastoid-cell lines produce an excess of free 
P40 chain, in addition to the biologically active heterodimer 
(1,  4). 
NKSF exerts a variety of biological functions on human 
T  and NK cells and possibly on other cell types. In partic- 
ular, it has been shown to: (a) induce IFN-3' production from 
both T  and NK cells and synergize in this effect with I1.-2, 
mitogens,  phorbol  diesters,  anti-CD3  antibodies,  and  al- 
logeneic antigens (1, 2, 6); (b) exert a comitogenic effect on 
fresh resting T cells together with lectins or phorbol diesters 
(1, 2);  (c) mediate a direct mitogenic effect on activated T 
or NK cell blasts (5, 7, and our unpublished results); (d) en- 
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cells (1, 2); (e) synergize with Ib2 in the generation of LAK 
cells (4). 
NKSF, independently or synergistically with other stimuli, 
enhances the in vitro responsiveness of both T and NK cells, 
acting as an immunostimulating lymphokine at the level of 
proliferation,  cytotoxic activity,  and  production  of lym- 
phokines. If NKSF is produced by normal B cells upon anti- 
genic stimulation, it could play an important regulatory role 
in T-B cell interaction, synergizing with IL-2 and antigens 
to stimulate T  cells during an immune response. 
PBL from HIV-infected patients have often a reduced NK 
cell cytotoxic activity (8-11) and the ability to produce IFN-y 
(12-16). These reduced functions of PBL from HIV-infected 
patients can be explained only in part by a specific depletion 
of the lymphocyte subsets mediating these functions (16-19) 
and suggest that T and NK cells in the patients are function- 
ally anergic. Identification of lymphokines with stimulating 
activity on the lymphocytes of HIV-infected patients has im- 
portant practical  implications. NKSF, alone or in combina- 
tion with other stimuli, might represent a possible  stimu- 
lant  of several functions of lymphocytes of HIV-infected 
patients. 
In this study, we analyze the enhancing effect of NKSF 
on the cytotoxic activity of PBL from healthy donors and 
HIV-infected patients. NKSF, at concentrations as low as 10 
pg/ml, rapidly (<4 h) and efficiently  enhanced the cytotoxic 
activity of  peripheral blood NK cells against a variety of target 
cells. The depressed  cytotoxic activity of PBL from HIV- 
infected patients is efficiently  enhanced by NKSF against both 
tumor-derived and virus-infected target cells to levels com- 
parable  with those mediated by PBL from control healthy 
donors. NKSF also induced IFN-3' production from the PBL 
of HIV-infected patients, although at lower levels than from 
PBL from healthy donors. 
Materials and Methods 
Patients.  29 consenting adult patients, positive for HIV anti- 
bodies and at various stages of the disease, were enrolled in this 
study. HIV serology was determined using commercially  available 
assays. All patients were repeatedly  positive  for HIV antibodies  using 
HIV ELISA, and confirmed by immunofluorescence  and Western 
blot analysis. Patient classification  was according to their absolute 
CD4 + cell counts (<200/mm  3, between 200 and 500/mm  3, higher 
than  500/ram3). CD4 +  and  CD8 + lymphocyte subsets were 
enumerated by immunofluorescence. Healthy HIV-seronegative 
donors, matched for age and sex, were included as controls. At 
the time of the study, none of the patients were receiving lym- 
phokine therapy. 
l~pheral Blood Lymphocytes.  Peripheral  blood was obtained  from 
consenting adult healthy donors and patients using heparin as an- 
ticoagulant. PBMC were separated on Ficoll-Hypaque  density gra- 
dient (Lymphoprep;  Nygaard and Co., Oslo, Norway). PBL were 
obtained from PBMC after partial depletion of monocytes by ad- 
herence to plastic surfaces (45 min, 37~  Positive and negative 
selection of PBL subsets reacting with mAbs was performed using 
antiglobulin indirect rosetting and gradient separation, as described 
(20). Cell preparations obtained by this method are >95%  pure. 
790 
The mAbs used in this study were B36.1 (IgG2b, anti-CDS) and 
B73.1 (IgG1, anti-CD16). 
To test the effect of lymphokines on cytotoxic activity, PBMC, 
PBL, or PBL subsets were incubated (5  x  10  ~ cells/ml in RPMI 
1640/10% FCS 37~  for the indicated times in the presence or 
absence of NKSF or other lymphokines. In some experiments, cell- 
free supernatant fluids were collected from 18-h cultures and ana- 
lyzed for IFN-3, content by ILIA (21). 
Cytokines and Cytoleine Assays.  Human rlL-2 (107 U/mg) was 
kindly provided by Dr. T. Taguchi, (Osaka University and Takeda 
Chemical Industry, Inc., Osaka,  Japan). Four different  preparations 
of NKSF were used in this study. Pure natural (n)NKSF (4  x  106 
U/ml) was purified from the cell-free superuatant fluid of this 
phorbol diester-stimulated RPMI 8866 B lymphoblastoid cell line 
according to Kobayashi et al. (1). In some experiments, a semi- 
purified nNKSF preparation was used, obtained after a two-step 
purification utilizing hydroxylapatite and Mono Q ion exchange 
chromatography. The IFN-3,-inducing  and NK cell-enhancing ac- 
tivities of this semipurified preparation were completely blocked 
by neutralizing  polyclonal  or monoclonal  antibodies  prepared against 
the recombinant 40-kD chain of NKSF (2, and our unpublished 
results). Two preparations of rNKSF were used: crude supernatant 
fluid from transfected COS cells (250 U/ml) or purified cytokine 
from transfected CHO cells (107 U/mg) (2). 
IFN-'y was measured  by ILIA  as previously  described  (21). NKSF 
biological activity was measured in an IFN-3, induction assay (1, 
6).  Briefly, PBL (106 cells/200 /~l/well) were incubated (18  h, 
37~  with NKSF dilutions in round-bottomed 96-well microtiter 
plates (Costar, Cambridge, MA). After incubation, triplicate 50- 
/~1 samples of  the call-free  supernatants were collected  for each well 
and IFN-~/was measured  by ILIA. 1 U of NKSF activity is defined 
as the amount required to induce half-maximal  IPN-'y production. 
To eliminate interexperimental variability in the determination of 
NKSF units, a laboratory standard of pure nNKSF was used. 1 U 
NKSF correspond to 3.6 pM of this standard  nNKSF preparation (1). 
Cell-mediated Cytotoxkity Assays.  saCr  release cytotoxic assays 
with K562, RDMC, Daudi cells, and human CMV-infected  fibro- 
blasts (CMV-FS4) were performed as described previously (1, 22) 
using as effector cells PBMC or PBL, from patients and healthy 
donors, pretreated or not with rNKSF or other lymphokines.  K562, 
RDMC, and Daudi cell lines were maintained in ILPMI 1640 con- 
taining  10%  FCS and  labeled overnight with Na2SaCrO4 (50 
#Ci/106 ceils; ICN Radiochemical, Irvine, CA); SlCr release was 
measured after 3 or 4 h of incubation. 
Human  embryonic  foreskin fibroblasts (FS4 strain; kindly 
provided byJ. Vilcek, New York Medical Center, New York, NY) 
were maintained  in Eagle's Modified  MEM (Flow Laboratories,  Inc., 
McLean, VA) supplemented with 10% heat-inactivated FCS and 
double vitamins. FS4 cells were used at passage 16-24. Monolayers 
of FS4 cells in  75-cm  2 flasks were infected with human CMV 
strain AD-169 at a multiplicity of infection of "~0.1. When 90% 
of the cells exhibited cytopathic effect, the monolayers  were tryp- 
sinized, and the cells were washed and frozen at  -120~  until 
use. Cryopreserved  CMV-infected  targets were thawed and labeled 
with NaeSlCrO4 (50/~Ci 106 cells) for 1 h at 37~  5% CO2 with 
gentle shaking every 15 min. Plates were centrifuged at 100 g for 
5 min and then incubated for 18 h at 37~  5% COz. All deter- 
minations were in triplicate. 
Percent specific SlCr release was calculated using the formula: 
percent specific SlCr release =  100x [(cpm experimental -  cpm 
spontaneous)/(cpm maximum -  cpm spontaneous)], where spon- 
taneous release was that obtained from target cells incubated with 
medium alone, and maximum release  was that obtained from target 
cells incubated with 1% Triton X-100. 
NK Cell Cytotoxicity  Enhancement  by NK Cell Stimulatory  Factor Results 
Enhancement of NK Cell-mediated Cytotoxicity by NKSE 
Pretreatment with NKSF for 18 h enhances the spontaneous 
cytotoxicity  of human PBL against a variety  of target  cell 
lines, including K562, Daudi, RDMC  (1), Raji, U937, and 
HL-60 (results not shown). The experiments described in this 
paper have been performed using as target cells the first three 
cell lines. Although the three cell lines differ in their senti- 
tivity to NK cells, comparable results have been obtained using 
each of them and representative experiments with only one 
target cell line are shown. To identify the cytotoxic effector 
calls  responding  to  stimulation  with  NKSF,  PBL  subsets 
reacting with mAbs to surface differentiation antigens were 
separated by indirect rosetting and tested for ability to mediate 
cytotoxicity.  These experiments  showed that the increased 
cytotoxicity of PBL treated with NKSF was mediated mainly 
by CD16+CD5 -  ceils (Fig. 1). The enhancement of NK cell 
cytotoxicity was observed with doses of NKSF as low as 0.1 
U/ml  ('~,0.4 pM) using both natural or recombinant  (Fig. 
2)  NKSF.  The  simultaneous  addition  of NKSF  and  IL-2 
resulted in only a negligible increase in the cytotoxic activity 
induced by optimal doses of NKSF (Fig. 2). However, in the 
presence of 100 or  1,000 U/ml  of IL-2,  doses  of NKSF  as 
low as 0.1  U/ml  were able to increase NK cytotoxicity  as 
efficiently as 2.5  U/ml  of NKSF  alone  (Fig.  2). 
Effect of NKSF on PBL from HIV-infected Patients.  To de- 
termine whether NKSF can modulate NK cell cytotoxic ac- 
tivity of HIV-infected patients, cytotoxicity assays were per- 
100-  A  CD16+/-  Effector  Cells  B  CD5+/-  Effector  Cells 
formed. NK cell cytotoxicity activity of healthy subjects against 
K562  cells  (E/T  ratio,  50:1)  varies  widely  (range  9-69%, 
StCr release).  PBL of HIV-infected patients mediate,  on av- 
erage, lower cytotoxicity against K562 and CMV-FS4 target 
cells than that mediated by PBL from a panel of 20 healthy 
(HIV-seronegative)  donors (40.9% vs. 17.5% against K562 
target cells [t =  5.56, p < 0.001] and 26.8% vs. 10.5% against 
CMV-FS4 target cells [t =  2.83,/~ < 0.05]) (Table 1, Figure 3). 
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Figure 1.  Effect  of NKSF  on the cytotoxic activity of CD16+CD5 - 
NK cells. Total PBL were separated into CD16 + and CD16-, and into 
CD5 + and CD5- cells by indirect rosetting.  The PBL and the separated 
subpopulations were incubated (37~  18 h, 5  x  106 ceUs/ml) in RPMI 
1640 10% FCS in the presence (filled symbols) or absence (open symbols) 
of I U/ml semipuritied NKSE Ceils were then washed and tested as effector 
ceUs in a 3-h cytotoxicity assay against slCr-labded  RDMC target calls. 
(A) Cytotoxicity of PBL and CD16 + and CD16-  cells separated using 
antibody B73.1. (B) cytotoxicity of PBL and CD5 + and CD5- cells sepa- 
rated using antibody B36.1.  The effector cell preparations were: unsepa- 
rated PBL (O, 0); antibody-positive cells (71, B); and antibody-negative 
cells (A, A). This experiment is representative  of four with similar results. 
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Effects of natural and recombinant NKSF and of IIr  on the 
cytotoxic activity of human PBL. (A) Fresh PBL were incubated (37~ 
18 h, 5  x  106 cells/ml in RPMI  1640 10% FCS) in medium without 
or with 10, 100, or 1,000 U/ml rlL-2, as indicated, in the absence of NKSF 
(O) or in the presence of 0.1 U/ml (e); 0.5 U/ml (A); and 2.5 U/ml 
(.)  semipurified nNKSF. PBL were then washed and tested in a 3-h slCr 
release assay against RDMC cells. This experiment  is representative of 
eight experiments performed using either RDMC or Dandi target cells. 
(B) Fresh PBL were incubated (37~  18 h, 5  x  10  e ceUs/ml in RPMI 
1640 10% FCS) in medium without (O) or with 30 pg/ml (e), 270 pg/ml 
(A), 2,430 pg/ml (E) purified CHO rNKSF, or 100 U/ml (A), 500 U/ml 
(71) rlL-2. PBL were then washed and tested in a 4-h SlCr release assay 
against slCr-labeled K562 cells. This experiment is representative of four 
experiments  performed with similar results. 
791  Chehimi et al. Table  1.  Effect of rNKSF and rlL-2 on Cytotoxicity  Mediated by PBL against K562 and CMV-FS4  Target  Cells 
PBL preincubated  with:* 
Target  Donors  CD4 +/mm  3  n  Medium  NKSF  IL-2  NKSF  +  IL-2 
K562  Healthy  ND  20  40.9  _+  13.0~  56.4  +  11.3  58.2  +  11.7  61.3  _+  10.0 
HIV infected  All donors  29  17.5  _+  15.5  40.7  +  14.6  37.1  +  14.0  49.7  _+  15.5 
<200  16  16.3  +  16.0  44.6  _+  13.0  36.0  _+  13.5  51.0  +  14.0 
200-500  9  18.6  _+  9.9  33.0  _+  12.7  35.0  _+  9.3  41.4  _+  14.0 
>500  4  29.3  _+  15.6  46.3  _+  15.5  45.3  _+  15.5  54.0  +_  14.0 
CMV-FS4  Healthy  ND  6  26.6  _+  12.0  43.6  +_  11.0  55.6  _+  9.0  60.5  _+  14.0 
HIV infected  All donors  6  10.5  _+  7.0  27.0  _+  7.0  23.0  _+  8.0  38.8  _+  11.0 
<200  5  7.6  _+  3.9  24.8  _+  5.5  22.8  _+  9.0  39.4  +  12.0 
>500  1  25  39  26  36 
*  PBL were preincubated  (18 h,  37~  with 1 U/ml rNKSF (COS cell derived),  100 U/ml rlL-2, or both cytokines.  After washing, PBL were 
used  as effector cells in a 4-h slCr release assay against  K562  target cells or in an  18-h  slCr release against  CMV-FS4 target cells. 
t Mean  percent  specific slCr-release  _+  SD (E/T ratio,  50:1)  of n donors  tested. 
The cytotoxic activity mediated by PBL from HIV-infected 
patients against K562 was significantly increased by incuba- 
tion with 1 U/ml ofrNKSF (t =  5.968, p < 0.001) to values 
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Figure 3.  Effect of NKSF on the cytotoxic activity of PBL from healthy 
(HIV-seronegative) donors and HIV-infected patients. PBL were incubated 
(37~  18 h, 5  x  106 cells/ml) in RPMI 1640 10% FCS with or without 
1 U/ml rNKSF (COS cell supernatant).  Cells were then washed and tested 
at an E/T cell ratio of 50:1 against  slCr-labeled  K562 in a 4-h cytotox- 
icity assay. HIVoinfected donors were grouped according to the absolute 
number of CD4 § cells/mm  3. Each pair of symbols represents a different 
donor. In each experiment,  a similar number of healthy controls and HIV- 
infected patients  was analyzed.  Healthy controls  were matched  for age 
and sex with the HIV-infected  patients. 
comparable with those observed with untreated PBL from 
control healthy donors, although still significantly lower (t 
=  4.06, p  <  0.001) than those mediated by NKSF-treated 
PBL  from  healthy  donors.  Killing  of  CMV-FS4  was 
significantly increased after preincubation of PBL from HIV- 
infected patients with 1 U/ml of NKSF (t =  4.08, p < 0.01). 
The dose of 1 U/ml of NKSF was as efficient as 100 U/ml 
of IL-2 in enhancing the cytotoxicity from HIV-infected pa- 
tients against K562 as well as CMV-FS4 target cells. Treat- 
ment of PBL with both NKSF and I1:2 resulted in a higher, 
but less than additive, enhancement of  cytotoxicity  when com- 
pared with treatments with each cytokine alone (Table  1). 
When K562 target cells were used, there was no significant 
difference in  response between  patients  with  CD4 +  cell 
counts <200/ram  3, and those having CD4 § cell counts be- 
tween 200 and 500/ram  3.  The number of patients tested, 
using CMV-FS4 target cells, was too low to evaluate the differ- 
ences among the three groups. 
The ability of PBL from nine healthy subjects, and 12 pa- 
tients already tested for cytotoxicity, to produce IFN-'y in 
response to NKSF and I1:2 was compared. Stimulation with 
100 U/ml of II:2 or with 1 U/ml of NKSF for 18 h resulted 
in an IFN-'y production from PBL of HIV-infected patients 
that was 5- to 10-fold lower than that from PBL of control 
healthy donors (Table 2).  Although simultaneous stimula- 
tion of PBL from HIV-infected patients with NKSF and I1:2 
induced a mean titer of 153 U/ml, this amount was approxi- 
mately sixfold lower than that observed after stimulation of 
PBL from healthy subjects (Table 2).  Patients with CD4 § 
cell counts >500/mm  3 produced higher amounts of IFN-',/ 
than those with lower CD4 + cell counts.  In the three pa- 
tients' groups tested, simultaneous stimulation with NKSF 
and IL-2 induced higher IFN-3' production than that induced 
by each cytokine alone (Table  2). 
792  NK Cell Cytotoxicity Enhancement  by NK Cell Stimulatory Factor Table  2.  Production of IFN-  T  by PBL from Healthy Controls and HIV-infected Patients Induced by NKSF and~or IL-2 
PBL incubated with:* 
Donors  CD4 +/mm  3  n  Medium  NKSF  IL-2  NKSF + IL-2 
U/ml IFN-7 
Healthy  ND  9  2.6 +_ 2.1~  92.3 _+ 101.0  99.8 + 119.0  895.5 _+ 236.0 
HIV infected  All donors  12  0.3 _+ 0.6  9.9 + 9.4  18.6 _+ 23.6  153.7  + 118 
HIV infected  <200  5  <0.3  4.4 + 4.0  2.1 _+ 4.0  86.6 + 58.0 
HIV infected  200-500  4  <0.3  6.0 _+ 2.5  10.5  _+ 8.0  129.5 _+ 44.3 
HIV infected  >500  3  1.0 + 0.8  24.3 _+ 5.5  57.0 _+ 9.9  298.0 _+ 135.0 
" IFN-3, concentration  was measured by RIA in the cell-free  supernatant fluid  collected  from PBL cultured (18 h, 37~  with or without rNKSF 
(COS cell derived), 1 U/ml; rib2,  100 U/ml; or both cytokines. 
* Mean + SD of n donors. 
Discussion 
IFN-ol and IFN43 were the first cytokines shown to en- 
hance NK cell-mediated cytotoxic activity (23).  Later, I1:2 
and TNF were also shown to be stimulatory (24-26).  IFN- 
and I1:2-induced enhancement of cytotoxicity occurs with 
fast kinetics (a few hours to 1-2 d), and in the absence of 
cell division (25). In these conditions, IFN and I1:2 increase 
the  cytotoxic  activity  of  the  NK  cell  subset,  mostly 
CD16+CD56+CD3 -  lymphocytes, and do not induce cyto- 
toxic activity in the majority of CD3 § T  cells, which do 
not mediate spontaneous cytotoxicity (25). 
Similarly to IFN-a and I1:2, NKSF is a potent stimulator 
of NK cell cytotoxic functions of PBL, acting with a rapid 
kinetics (<4 h) and at extremely low concentrations. Our 
data show that in an 18-h incubation period, NKSF increases 
the cytotoxic activity of CD16+CD5 -  NK cells, but does 
not confer this function to CD16-CD5 + T cells. As we pre- 
viously reported for natural NKSF (1), and confirm now using 
pure recombinant cytokine, NKSF efficiently enhances NK 
cell-mediated cytotoxicity at concentrations <1 pM, whereas 
similar effects are observed with I1:2 or IFN-ol only when 
these cytokines are used at concentrations at least 100-fold 
higher. Because NKSF synergizes with I1:2 to induce IFN-'y 
production from both T  and NK cells (1, 6),  it was of in- 
terest to assay whether the two lymphokines synergize in 
enhancing cytotoxic activity. PBL stimulated with optimal 
concentrations of  both 11:2 and NKSF mediated only margi- 
nally higher cytotoxicity than PBL stimulated with NKSF 
alone. However, in the presence of 100 or 1,000 U/ml of I1:2, 
a maximal stimulation of cytotoxic activity was obtained with 
concentrations of NKSF (0.1 U/ml or 0.35 pM) that by them- 
selves induce only a modest enhancement. 
As previously observed after stimulation with IFN-a or 
II:2  (20,  25),  only the cytotoxicity of CD16 § CD5-  NK 
cells is enhanced by NKSF and no cytotoxic ability is induced 
in the CD5 § T cells at the time points tested. Gubler et al. 
(5) have described a strong synergistic activity of NKSF and 
I1:2 in inducing generation of cytotoxic cells against Daudi 
target cells in a 4-d culture. Whether these activated cyto- 
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toxic cells are mostly composed of CD16 § NK cells, as ob- 
served in other systems of LAK cell generation, or contain 
a significant proportion of non-MHC-restricted T  cells, re- 
mains to be determined. 
Infection with HIV is associated with a wide spectrum 
of clinical stages ranging from asymptomatic illness to full- 
blown AIDS.  In AIDS patients,  a multitude of profound 
defects in the various compartments of the immune system 
have been described (27).  Some of the dysfunctions include 
a depression in CD4 § T lymphocytes number and function, 
and a decrease in monocyte functions, NK cell cytotoxic ac- 
tivity, lymphoproliferative responses to mitogens and aUoan- 
tigens, MHC class II antigen expression,  and polyclonal B 
cell activation (27). In vitro, the production of lymphokines 
such as IFN-ol, IFN-3,, and I1:2 is diminished (12-16,  28). 
The nature and role of humoral and cellular immune response 
mechanisms against HIV have not been fully characterized. 
It is increasingly evident that in vivo progression of AIDS 
is intimately related with abnormal functioning of the im- 
mune system. Tremendous efforts are being made to develop 
new effective immunomodulatory  agents that, in association 
with antiretroviral drugs, may be of beneficial therapy.  Sev- 
eral groups have previously used I1:2 alone in HIV-infected 
patients with varying results, and other groups are currently 
studying the effects of AZT and 11:2 in individuals infected 
with HIV (29-32).  However, I1:2 at doses between 1 and 
12  x  106 U/m  2 can cause serious side effects. One approach 
to improving the efficacy of I1:2 therapy while reducing its 
toxicity is to use a combination of cytokines or a combina- 
tion of a cytokine with antiretroviral drugs. 
Conflicting data have been reported concerning NK cell 
cytotoxic activity in patients with AIDS (33), although most 
studies have reported NK cell defects,  the pathogenesis of 
which is still unknown. We have previously reported data 
on the susceptibility of clonal and polyclonal populations of 
NK cells to HIV infection, suggesting that loss of NK cells 
and reduced NK cell functions in patients with AIDS occur 
via two different mechanisms (22). In the present study, we evaluated  the  in  vitro  effect  of NKSF  and  IL-2 on  NK 
cell-mediated activity and on IFN-3, production by PBL from 
HIV-infected patients.  Since the mechanisms involved in killing 
of virus-infected targets are different from those involved in 
lysis of tumor cells, we used K562 cells and CMV-infected 
fibroblasts, CMV-FS4, as target cells. Our results indicate that 
HIV-infected patients showed a deficiency in NK cell-medi- 
ated cytotoxicity against both target cells, which is in agree- 
ment with other studies (33). We did not find a clear corre- 
lation  between  the  level  of cytotoxicity and  the  absolute 
number of CD4 §  T  lymphocytes. Using NKSF at  a con- 
centration  of 1 U/ml,  our data revealed  an increase in NK 
cell-mediated cytotoxicity in all HIV-infected patients tested. 
A similar effect was achieved with 100 U/ml of Ib2. Of in- 
terest, NKSF restores NK activity of HIV-infected patients 
to a level similar to that observed with healthy subjects. NKSF- 
dependent enhancement  of NK cell cytotoxicity in normal 
donors and in patients was completely blocked by two different 
neutralizing  mAbs  to rNKSF  (not  shown).  Depletion  of 
CD16 + NK cells from NKSF-stimulated PBL of patients or 
controls reduced the cytotoxicity against K562 and CMV- 
FS4 to baseline levels  (not  shown). 
When Ib2 and NKSF were used separately,  the levels of 
IFN-'y production from 12 HIV-infected patients tested were 
5- to 10-fold lower than those of healthy donors; stimulation 
with both cytokines synergistically induced IFN-3' at levels 
higher  than  those  observed in  healthy  donors  with  each 
cytokine alone. IFN-3, production in patients with AIDS cor- 
related with  the absolute CD4 §  cell number. 
Clinical trials using IFN-3, in patients with AIDS (34, 35) 
have been initiated  on the basis of the observation that  al- 
though the patients have a defect in their ability to produce 
IFN-'r in response to different inducers,  their PBMC were 
responsive to IFN-3, in vitro (12, 36-38). Heagy et al. (35) 
reported a phase I/II study in which 21 AIDS patients were 
treated with IFN-3,.  In six patients,  a decrease in p24 core 
antigen was observed, suggesting an antiviral effect of IFN-y. 
In patients with high CD4 + cell counts, a transient regres- 
sion of the malignant lesions associated with Kaposi sarcomas 
was also observed. Murphy et al. (34) reported that IFN-3,- 
treated patients have fewer nonopportunistic infections than 
the IL-2-treated ones. 
It is clear that the treatment of a syndrome with multiple 
immunological dysfunctions such as AIDS would be facili- 
tated by the combined use of multiple cytokines and antiviral 
agents that would offer the possibility to correct or compen- 
sate some of the dysfunctions while exerting a direct antiviral 
effect. NKSF is one such potential candidate cytokine because 
of its multiple immunopotentiating effects, its activity at much 
lower concentrations than other cytokines, and, particularly 
important,  its ability to synergize with other physiological 
stimuli on immune cells, such as IL-2 or antigenic stimulation. 
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